Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Investor Presentation (November 2026)
27 slides from Aquestive Therapeutics's investor presentation, Nov 5, 2026
Slide 1: Corporate Presentation November 2026
Corporate Presentation November 2026
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statem
Slide 3: Who we are
3 Who we are A publicly traded biopharmaceutical company (NASDAQ: AQST) focused on advancing medicines to bring meaningful improvement to patients' lives through innovative science.
Slide 4: Advancing Medicines to Bring Meaningful Improvement to Patients' Lives
Advancing Medicines to Bring Meaningful Improvement to Patients’ Lives 4 1. Company estimate of potential peak annual net sales in a given year, assuming regulatory approval and successful commercialization; not a revenue forecast. Includes potential Libervant net sales to be recorded by our license
Slide 5: Our Technologies
Our Technologies PharmFilm® 5 PharmFilm® is a unique and versatile technology for high-performance drug delivery. Aquestive scientists combine the customizable features of PharmFilm® with patented formulation and engineering processes to optimize the delivery of active pharmaceutical ingredients (AP
Slide 6: Our Products
Our Products 1. Ondif collaboration with Hypera-Pharma (Brazil). 2. Sympazan collaboration with Cosette Pharmaceuticals, Inc. (worldwide). 3. Emylif collaboration with Zambon (EU). 4. Suboxone collaboration with Indivior (worldwide). 6 Aquestive is the go-to formulation development and commercial ma
Slide 7: Diversified Pipeline Fuels Our Growth Plan
Diversified Pipeline Fuels Our Growth Plan 7 1. Company estimates of potential peak annual net sales and annual U.S. product sales, as applicable, in a given year, assuming regulatory approval and successful commercialization; not forecasts of revenue for any period. Actual results may differ materi
Slide 8: Dedicated and Experienced Leadership Team
Dedicated and Experienced Leadership Team 8 Daniel Barber President, CEO & Director Matthew Greenhawt Chief Medical Officer Peter Boyd Chief People Officer Melina Cioffi SVP, Regulatory Affairs Sherry Korczynski Chief Commercial Officer Matthew Davis Chief Development Officer Ernie Toth Chief Financ
Slide 9: Cash Position Supports Anaphylm Review and Launch Preparation
Cash Position Supports Anaphylm Review and Launch Preparation 9 $90.3 million in cash and cash equivalents as of September 30, 2026 Potential access to $75 million under a strategic funding agreement with RTW Investments, subject to applicable conditions including FDA approval of Anaphylm An additio
Slide 10: Lead Asset Anaphylm (dibutepinephrine) sublingual film
Lead Asset Anaphylm (dibutepinephrine) sublingual film 10 ANAPHYLM (dibutepinephrine) sublingual film is an investigational product candidate that has not been approved by the U.S. Food and Drug Administration. Safety and efficacy have not been established. Statements regarding potential benefits, c
Slide 11: A Novel Approach to Epinephrine Delivery
A Novel Approach to Epinephrine Delivery Anaphylm (dibutepinephrine) sublingual film Needle-Free Easy to Use Designed to Work Quickly1 Device-Free Easy to Carry 1. Aquestive Therapeutics data on file. First and only non-device, orally delivered epinephrine product candidate 11 ANAPHYLM (dibutepineph
Slide 12: Anaphylaxis: a rapid-onset, life-threatening allergic reaction
Anaphylaxis: 12 1. Xiaowei Liu , Sangil Lee , Christine M Lohse , Cassandra T Hardy , Ronna L Campbell Biphasic Reactions in Emergency Department Anaphylaxis Patients: A Prospective Cohort Study, DOI: 10.1016/j.jaip.2019.10.027 2. Shaw, Maggie L, Gaps in Anaphylaxis Care, Epinephrine Use Highlight R
Slide 13: The epinephrine market continues to grow
1. U.S. Epinephrine for Anaphylaxis Treatment Market Size, Share & Industry Analysis; Fortune Business Insights, Mar 23, 2026; https://www.fortunebusinessinsights.com/u-s-epinephrine-for-anaphylaxis- treatment-market-110494 2. Symphony Health Data through 12/31/2025, Metys National Projected Data, A
Slide 14: Challenges with Current Epinephrine Auto-Injectors (EAIs)
Challenges with Current Epinephrine Auto-Injectors (EAIs) 1. Golden DBK, et al. (2024). Ann Allergy Asthma Immunol, 132(2), 124–176. 2. Pouessel G, et al. (2025). Clin Exp Allergy, 55(1), 36–51. 3. Lieberman JA, et al. (2023). Ann Allergy Asthma Immunol, 131(2), 185–193.e10. 4. Wang J. (2024). J Foo
Slide 15: Rapid Relief Needed When It Matters Most
Rapid Relief Needed When It Matters Most1 1. Aquestive data on file; Neffy® T-max data are from its approved labeling. Cross-study comparisons are not head-to-head, and no conclusions regarding comparative efficacy, equivalence or superiority should be drawn. Therapeutic blood concentrations do not
Slide 16: 96% of Survey Respondents Preferred Film in a Hands-on Preference Survey
96% of Survey Respondents Preferred Film in a Hands-on Preference Survey1,2 51 1 1 PREFER FILM PREFER FILM & NASAL EQUALLY PREFER NASAL Survey Results 1. Aquestive Therapeutics data on file. 2. Survey results reflect stated respondent preferences under controlled survey conditions and should not be
Slide 17: Launch Readiness Planning, if Anaphylm is Approved
Launch Readiness Planning, if Anaphylm is Approved 2026 2027 Potential Commercial Launch Planning • Planning potential payer access • Identifying key prescribers for a potential launch • Planning engagement with HCPs, patients, caregivers and advocacy groups, if approved • Preparing a focused potent
Slide 18: Anaphylm Regulatory Milestones
Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027 • Anaphylm advances toward a March 16, 2027, PDUFA goal date following FDA acceptance of the NDA resubmission. • Ex-U.S. filings are targeted for Can
Slide 19: AQST-108 (epinephrine) Topical Gel
AQST-108 (epinephrine) Topical Gel 19
Slide 20: AQST-108 (epinephrine) Topical Gel
AQST-108 (epinephrine) Topical Gel 1. Jeong, W.Y., Kwon, M., Choi, H.E. et al. Recent advances in transdermal drug delivery systems: a review. Biomater Res 25, 24 (2021). 2. Aquestive Therapeutics data on file. 3. See Investor Day Presentation dated September 27, 2024, located at Aquestive.com/inves
Slide 21: AQST-108 has the potential to harness the benefits of a topical gel with prodrug technology
AQST-108 has the potential to harness the benefits of a topical gel with prodrug technology1 Administration process • Topical gel applied to affected skin (epidermis) • AQST-108 penetrates to dermis layer and converts slowly over time • AQST-108 is hypothesized to convert via interstitial esterases
Slide 22: AQST-108 Activity Where AD Triggers Converge
AQST-108 Activity Where AD Triggers Converge Topical epinephrine prodrug: hypothesized modulation of a mast-cell pathway Other AD therapies address selected triggers or mediators. AQST-108 is hypothesized to act at a point of convergence. MANY TRIGGERS • Allergen / IgE • Scratching, neuropeptides •
Slide 23: Atopic Dermatitis (AD) Treatment Landscape
Atopic Dermatitis (AD) Treatment Landscape 23
Slide 24: ~27.5M prevalent AD patients, ~3M actively managed
~27.5M prevalent AD patients, ~3M of whom are actively managed; ~90% of patients have mild-moderate AD, which is historically pharmacologically underserved 1. Chiesa Fuxench ZC et al., Atopic Dermatitis in America Study: A Cross-Sectional Study J Invest Dermatol. 2019 Mar;139(3):583-590. doi: 10.101
Slide 25: The AD market remains receptive to therapies that address unmet needs
The AD market remains receptive to therapies that address unmet needs *Does not specify mild-moderate on-label TEAEs = Treatment-Emergent Adverse Events; FDA on-label indications, accessed May 2026; AQST-108 TPP; Market Research Interviews conducted June-July 2026, N=20 HCPs and N=10 Patients/Caregi
Slide 26: Potential Future Market Context Across Dermatologic and Immunologic Indications
Potential Future Market Context Across Dermatologic and Immunologic Indications 1. EvaluatePharma, accessed July 2026. Third-party market projections; not Aquestive revenue forecasts or projected AQST-108 revenue. Vtama sales not reported by EP. *Future indications are not currently in development.
Slide 27: Thank You
Thank You ce § Aquestive
Aquestive Therapeutics — Investor Presentation (November 2026) on 6ix